Strong expression association between matriptase and its substrate prostasin in breast cancer

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1604-1609

  Bergum, Christopher ^a   Zoratti, Gina ^a   Boerner, Julie ^a   List, Karin ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIPTASE; PROSTASIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIUM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84855748525     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22877     Document Type: Article

References (39)

1. Andreasen D, Vuagniaux G, Fowler-Jaeger N, Hummler E, Rossier BC. 2006. Activation of epithelial sodium channels by mouse channel activating proteases (mCAP) expressed in Xenopus oocytes requires catalytic activity of mCAP3 and mCAP2 but not mCAP1. J Am Soc Nephrol 17:968-976.
2. Antalis TM, Bugge TH, Wu Q. 2011. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 99:1-50.
3. Bruns JB, Carattino MD, Sheng S, Maarouf AB, Weisz OA, Pilewski JM, Hughey RP, Kleyman TR. 2007. Epithelial Na+ channels are fully activated by furin- and prostasin-dependent release of an inhibitory peptide from the gamma subunit. J Biol Chem 282:6153-6160.
4. Bugge TH, List K, Szabo R. 2007. Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front Biosci 12:5060-5070.
5. Buzza MS, Netzel-Arnett S, Shea-Donohue T, Zhao A, Lin CY, List K, Szabo R, Fasano A, Bugge TH, Antalis TM. 2010. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 107:4200-4205.
6. Chen LM, Skinner ML, Kauffman SW, Chao J, Chao L, Thaler CD, Chai KX. 2001. Prostasin is a glycosylphosphatidylinositol-anchored active serine protease. J Biol Chem 276:21434-21442.
7. Chen M, Fu YY, Lin CY, Chen LM, Chai KX. 2007. Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3. Biochim Biophys Acta 1773:1133-1140.
8. Chen M, Chen LM, Lin CY, Chai KX. 2008. The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim Biophys Acta 1783:896-903.
9. Chen LM, Hatfield ML, Fu YY, Chai KX. 2009. Prostasin regulates iNOS and cyclin D1 expression by modulating protease-activated receptor-2 signaling in prostate epithelial cells. Prostate 69:1790-1801.
10. Chen YW, Wang JK, Chou FP, Chen CY, Rorke EA, Chen LM, Chai KX, Eckert RL, Johnson MD, Lin CY. 2010. Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J Biol Chem 285:31755-31762.
11. Friis S, Godiksen S, Bornholdt J, Selzer-Plon J, Rasmussen HB, Bugge TH, Lin CY, Vogel LK. 2011. Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase. J Biol Chem 286:5793-5802.
12. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP. 1999. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 81:1328-1334.
13. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD, Shay JW. 1998. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 78:766-774.
14. Hoffmeyer MR, Wall KM, Dharmawardhane SF. 2005. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer Cell Int 5:11.
15. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. 2010. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121:53-64.
16. Hooper JD, Bowen N, Marshall H, Cullen LM, Sood R, Daniels R, Stuttgen MA, Normyle JF, Higgs DR, Kastner DL, Ogbourne SM, Pera MF, Jazwinska EC, Antalis TM. 2000. Localization, expression and genomic structure of the gene encoding the human serine protease testisin. Biochim Biophys Acta 1492:63-71.
17. Kiyomiya K, Lee MS, Tseng IC, Zuo H, Barndt RJ, Johnson MD, Dickson RB, Lin CY. 2006. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol 291:C40-C49.
18. Lacroix M, Leclercq G. 2004. Relevance of breast cancer cell lines as models for breast tumours: An update. Breast Cancer Res Treat 83:249-289.
19. Lee MS, Tseng IC, Wang Y, Kiyomiya K, Johnson MD, Dickson RB, Lin CY. 2007. Autoactivation of matriptase in vitro: Requirement for biomembrane and LDL receptor domain. Am J Physiol Cell Physiol 293:C95-C105.
20. Leyvraz C, Charles RP, Rubera I, Guitard M, Rotman S, Breiden B, Sandhoff K, Hummler E. 2005. The epidermal barrier function is dependent on the serine protease CAP1/Prss. J Cell Biol 170:487-496.
21. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, Engelholm LH, Behrendt N, Bugge TH. 2002. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21:3765-3779.
22. List K, Szabo R, Wertz PW, Segre J, Haudenschild CC, Kim SY, Bugge TH. 2003. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol 163:901-910.
23. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH. 2005. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes rasmediated malignant transformation. Genes Dev 19:1934-1950.
24. List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH. 2006. Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 168:1513-1525.
25. List K, Hobson JP, Molinolo A, Bugge TH. 2007. Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase. J Cell Physiol 213:237-245.
26. List K. 2009. Matriptase: A culprit in cancer? Future Oncol 1:97-104.
27. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, Bugge TH. 2009. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 175:1453-1463.
28. Netzel-Arnett S, Currie BM, Szabo, Lin CY, Chen LM, Chai KX, Antalis TM, Bugge TH, List K. 2006. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Bio Chem 281:32941-32945.
29. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. 1999. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147:631-644.
30. Oberst MD, Chen LY, Kiyomiya K, Williams CA, Lee MS, Johnson MD, Dickson RB, Lin CY. 2005. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 289:C462-C470.
31. Riggins RB, Zwart A, Roberts J, Ethier SP, Clarke R. 2005. SUM44-TAM: A new model of antiestrogen-resistant breast cancer. Proc Am Assoc Cancer Res 46.
32. Sanders AJ, Webb SL, Parr C, Mason MD, Jiang WG. 2010. The type II transmembrane serine protease, matriptase-2: Possible links to cancer? Anticancer Agents Med Chem 10:64-69. Review.
33. Shipway A, Danahay H, Williams JA, Tully DC, Backes BJ, Harris JL. 2004. Biochemical characterization of prostasin, a channel activating protease. Biochem Biophys Res Commun 324:953-963.
34. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. 1990. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line MCF-10. Cancer Res 50:6075-6086.
35. Szabo R, Rasmussen AL, Moyer AB, Kosa P, Schafer JM, Molinolo AA, Gutkind JS, Bugge TH. 2011. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 30:2003-2016.
36. Takeuchi T, Shuman MA, Craik CS. 1999. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 96:11054-11061.
37. Tang T, Kmet M, Corral L, Vartanian S, Tobler A, Papkoff J. 2005. Testisin, a glycosyl-phosphatidylinositol-linked serine protease, promotes malignant transformation in vitro and in vivo. Cancer Res 65:868-878.
38. Tong Z, Illek B, Bhagwandin VJ, Verghese GM, Caughey GH. 2004. Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15cells, acystic fibrosis airway epithelial cell line. Am J Physiol Lung Cell Mol Physiol 287:L928-L935.
39. Vallet V, Chraibi A, Gaeggeler HP, Horisberger JD, Rossier BC. 1997. An epithelial serine protease activates the amiloride-sensitive sodium channel. Nature 389:607-610.